Zenas BioPharma (NASDAQ:ZBIO) Trading 7.2% Higher – What’s Next?

Zenas BioPharma, Inc. (NASDAQ:ZBIO) shot up 7.2% during mid-day trading on Friday . The company traded as high as $29.91 and last traded at $30.2650. Approximately 248,670 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 854,336 shares. The stock had previously closed at $28.24.

Wall Street Analyst Weigh In

ZBIO has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings downgraded Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Finally, Morgan Stanley increased their price target on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zenas BioPharma presently has an average rating of “Moderate Buy” and an average target price of $44.29.

Zenas BioPharma Stock Performance

The firm has a market cap of $1.86 billion, a PE ratio of -3.49 and a beta of -0.96. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The company has a 50-day simple moving average of $21.79 and a two-hundred day simple moving average of $22.26.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the previous year, the business earned ($0.80) EPS. As a group, equities research analysts forecast that Zenas BioPharma, Inc. will post -4.47 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders have purchased a total of 120,000 shares of company stock worth $2,080,000 over the last three months. 22.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently added to or reduced their stakes in ZBIO. Bank of America Corp DE grew its position in Zenas BioPharma by 723.5% during the first quarter. Bank of America Corp DE now owns 388,347 shares of the company’s stock worth $7,592,000 after buying an additional 341,187 shares in the last quarter. Exome Asset Management LLC bought a new stake in shares of Zenas BioPharma during the 1st quarter valued at about $1,578,000. Quantinno Capital Management LP purchased a new position in shares of Zenas BioPharma during the first quarter worth about $413,000. Sei Investments Co. purchased a new position in shares of Zenas BioPharma during the first quarter worth about $242,000. Finally, Walleye Capital LLC purchased a new position in Zenas BioPharma in the 1st quarter worth approximately $2,448,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.